Global Psoriatic Arthritis Therapeutics Market 2019-2023

Detailed TOC of Global Psoriatic Arthritis Therapeutics Market 2019-2023

PART 01: EXECUTIVE SUMMARY              

PART 02: SCOPE OF THE REPORT              

2.1 Preface              

2.2 Preface              

2.3 Currency conversion rates for US$              

PART 03: MARKET LANDSCAPE              

Market ecosystem              

Market characteristics              

Market segmentation analysis              

PART 04: MARKET SIZING              

Market definition              

Market sizing 2018              

Market size and forecast 2018-2023              

PART 05: FIVE FORCES ANALYSIS              

Bargaining power of buyers              

Bargaining power of suppliers             s 

Threat of new entrants              

Threat of substitutes              

Threat of rivalry              

Market condition              

PART 06: PIPELINE              

PART 07: MARKET SEGMENTATION BY TYPE              

Market segmentation by type              

Comparison by type              

Biologics - Market size and forecast 2018-2023              

Small molecules - Market size and forecast 2018-2023              

Market opportunity by type              

PART 08: CUSTOMER LANDSCAPE              

PART 09: GEOGRAPHIC LANDSCAPE              

Geographic segmentation              

Geographic comparison              

North America - Market size and forecast 2018-2023              

Europe - Market size and forecast 2018-2023              

Asia - Market size and forecast 2018-2023              

ROW - Market size and forecast 2018-2023              

Key leading countries              

Market opportunity              

PART 10: DECISION FRAMEWORK              

PART 11: DRIVERS AND CHALLENGES              

Market drivers              

Market challenges              

PART 12: MARKET TRENDS              

Advent of regenerative therapy              

Genetic screening tests              

Increasing strategic alliances              

PART 13: VENDOR LANDSCAPE              

Overview              

Landscape disruption              

Competitive scenario             

PART 14: VENDOR ANALYSIS             

Vendors covered             

Vendor classification             

Market positioning of vendors             

AbbVie Inc.             

Celgene Corp.             

Johnson & Johnson Services Inc.             

Novartis AG             

Pfizer Inc.             

PART 15: APPENDIX             

Research methodology             

List of abbreviations             

Definition of market positioning of vendors             

PART 16: EXPLORE TECHNAVIO             

 

  

Exhibit 01:               Product overview              

Exhibit 02:               Global pharmaceuticals market              

Exhibit 03:               Segments of global pharmaceuticals market              

Exhibit 04:               Market characteristics              

Exhibit 05:               Market segments              

Exhibit 06:               Market definition - Inclusions and exclusions checklist              

Exhibit 07:               Market size 2018              

Exhibit 08:               Global market: Size and forecast 2018-2023 ($ millions)              

Exhibit 09:               Global market: Year-over-year growth 2019-2023 (%)              

Exhibit 10:               Five forces analysis 2018              

Exhibit 11:               Five forces analysis 2023              

Exhibit 12:               Bargaining power of buyers              

Exhibit 13:               Bargaining power of suppliers              

Exhibit 14:               Threat of new entrants              

Exhibit 15:               Threat of substitutes              

Exhibit 16:               Threat of rivalry              

Exhibit 17:               Market condition - Five forces 2018              

Exhibit 18:               Global psoriatic arthritis therapeutics market pipeline: Overview              

Exhibit 19:               Global psoriatic arthritis therapeutics market pipeline: Snapshot              

Exhibit 20:               Type - Market share 2018-2023 (%)              

Exhibit 21:               Comparison by type              

Exhibit 22:               Biologics - Market size and forecast 2018-2023 ($ millions)              

Exhibit 23:               Biologics - Year-over-year growth 2019-2023 (%)              

Exhibit 24:               Small molecules - Market size and forecast 2018-2023 ($ millions)              

Exhibit 25:               Small molecules - Year-over-year growth 2019-2023 (%)              

Exhibit 26:               Market opportunity by type              

Exhibit 27:               Customer landscape              

Exhibit 28:               Market share by geography 2018-2023 (%)              

Exhibit 29:               Geographic comparison              

Exhibit 30:               North America - Market size and forecast 2018-2023 ($ millions)              

Exhibit 31:               North America - Year-over-year growth 2019-2023 (%)              

Exhibit 32:               Top 3 countries in North America              

Exhibit 33:               Europe - Market size and forecast 2018-2023 ($ millions)              

Exhibit 34:               Europe - Year-over-year growth 2019-2023 (%)              

Exhibit 35:               Top 3 countries in Europe              

Exhibit 36:               Asia - Market size and forecast 2018-2023 ($ millions)              

Exhibit 37:               Asia - Year-over-year growth 2019-2023 (%)              

Exhibit 38:               Top 3 countries in Asia              

Exhibit 39:               ROW - Market size and forecast 2018-2023 ($ millions)              

Exhibit 40:               ROW - Year-over-year growth 2019-2023 (%)              

Exhibit 41:               Top 3 countries in ROW              

Exhibit 42:               Key leading countries              

Exhibit 43:               Market opportunity              

Exhibit 44:               Humira biosimilars expected launch in the US              

Exhibit 45:               Impact of drivers and challenges              

Exhibit 46:               Vendor landscape              

Exhibit 47:               Landscape disruption              

Exhibit 48:               Vendors covered             

Exhibit 49:               Vendor classification             

Exhibit 50:               Market positioning of vendors             

Exhibit 51:               AbbVie Inc. - Vendor overview             

Exhibit 52:               AbbVie Inc. - Business segments             

Exhibit 53:               AbbVie Inc. - Organizational developments             

Exhibit 54:               AbbVie Inc. - Geographic focus             

Exhibit 55:               AbbVie Inc. - Key offerings             

Exhibit 56:               AbbVie Inc. - Key customers             

Exhibit 57:               Celgene Corp. - Vendor overview             

Exhibit 58:               Celgene Corp. - Business segments             

Exhibit 59:               Celgene Corp. - Organizational developments             

Exhibit 60:               Celgene Corp. - Geographic focus             

Exhibit 61:               Celgene Corp. - Key offerings             

Exhibit 62:               Celgene Corp. - Key customers             

Exhibit 63:               Johnson & Johnson Services Inc. - Vendor overview             

Exhibit 64:               Johnson & Johnson Services Inc. - Business segments             

Exhibit 65:               Johnson & Johnson Services Inc. - Organizational developments             

Exhibit 66:               Johnson & Johnson Services Inc. - Geographic focus             

Exhibit 67:               Johnson & Johnson Services Inc. - Segment focus             

Exhibit 68:               Johnson & Johnson Services Inc. - Key offerings             

Exhibit 69:               Johnson & Johnson Services Inc. - Key customers             

Exhibit 70:               Novartis AG - Vendor overview             

Exhibit 71:               Novartis AG - Business segments             

Exhibit 72:               Novartis AG - Organizational developments             

Exhibit 73:               Novartis AG - Geographic focus             

Exhibit 74:               Novartis AG - Segment focus             

Exhibit 75:               Novartis AG - Key offerings             

Exhibit 76:               Novartis AG - Key customers             

Exhibit 77:               Pfizer Inc. - Vendor overview             

Exhibit 78:               Pfizer Inc. - Business segments             

Exhibit 79:               Pfizer Inc. - Organizational developments             

Exhibit 80:               Pfizer Inc. - Geographic focus             

Exhibit 81:               Pfizer Inc. - Segment focus             

Exhibit 82:               Pfizer Inc. - Key offerings             

Exhibit 83:               Pfizer Inc. - Key customers             

Exhibit 84:               Validation techniques employed for market sizing             

Exhibit 85:               Definition of market positioning of vendors